A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy (PCV).

Trial Profile

A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy (PCV).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Aflibercept (Primary) ; Verteporfin
  • Indications Retinal haemorrhage
  • Focus Therapeutic Use
  • Acronyms ATLANTIC
  • Most Recent Events

    • 19 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 07 Oct 2015 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017, according to ClinicalTrials.gov record.
    • 07 Oct 2015 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top